204 related articles for article (PubMed ID: 7688821)
21. Enhancement of the antibody response to flavivirus B-cell epitopes by using homologous or heterologous T-cell epitopes.
Roehrig JT; Johnson AJ; Hunt AR; Beaty BJ; Mathews JH
J Virol; 1992 Jun; 66(6):3385-90. PubMed ID: 1374807
[TBL] [Abstract][Full Text] [Related]
22. Human T-lymphotropic virus type 1 peptides in chimeric and multivalent constructs with promiscuous T-cell epitopes enhance immunogenicity and overcome genetic restriction.
Lairmore MD; DiGeorge AM; Conrad SF; Trevino AV; Lal RB; Kaumaya PT
J Virol; 1995 Oct; 69(10):6077-89. PubMed ID: 7545241
[TBL] [Abstract][Full Text] [Related]
23. Mapping of CD4
Bai L; Takeshima SN; Sato M; Davis WC; Wada S; Kohara J; Aida Y
Virol J; 2019 Dec; 16(1):157. PubMed ID: 31842930
[TBL] [Abstract][Full Text] [Related]
24. Bovine leukemia virus-gp51 antigen expression is associated with CD5 and IgM markers on infected lymphocytes.
Meirom R; Moss S; Brenner J
Vet Immunol Immunopathol; 1997 Oct; 59(1-2):113-9. PubMed ID: 9437829
[TBL] [Abstract][Full Text] [Related]
25. [Exposure of the major immunodominant epitope of the gp51 envelope protein of bovine leukosis virus on the surface of the hepatitis B core antigen capsid].
Ul'rikh R; Borisova GP; Siakkou Kh; Plattser K; Ose VP; Berzin' IG; Dreĭlinia DE; Pushko PM; Tsibinogin VV; Pumpen PP
Mol Biol (Mosk); 1991; 25(2):368-74. PubMed ID: 1715509
[TBL] [Abstract][Full Text] [Related]
26. Ovine MHC class II DRB1 alleles associated with resistance or susceptibility to development of bovine leukemia virus-induced ovine lymphoma.
Nagaoka Y; Kabeya H; Onuma M; Kasai N; Okada K; Aida Y
Cancer Res; 1999 Feb; 59(4):975-81. PubMed ID: 10029093
[TBL] [Abstract][Full Text] [Related]
27. Influence of epitope polarity and adjuvants on the immunogenicity and efficacy of a synthetic peptide vaccine against Semliki Forest virus.
Fernández IM; Snijders A; Benaissa-Trouw BJ; Harmsen M; Snippe H; Kraaijeveld CA
J Virol; 1993 Oct; 67(10):5843-8. PubMed ID: 7690411
[TBL] [Abstract][Full Text] [Related]
28. Antigenicity of subregions of recombinant bovine leukemia virus (BLV) glycoprotein gp51 for antibody detection.
Bai L; Soya M; Ichikawa M; Matsuura R; Arimura Y; Wada S; Aida Y
J Virol Methods; 2023 Jan; 311():114644. PubMed ID: 36332713
[TBL] [Abstract][Full Text] [Related]
29. Characterization of T- and B-cell epitopes of a simian retrovirus (SRV-2) envelope protein.
Malley A; Werner L; Benjamini E; Leung CY; Torres J; Pangares N; Shiigi S; Axthelm M
J Med Primatol; 1991 Jun; 20(4):177-81. PubMed ID: 1719205
[TBL] [Abstract][Full Text] [Related]
30. Peptide-based bovine leukemia virus (BLV) vaccine that induces BLV-Env specific Th-1 type immunity.
Ohishi K; Kabeya H; Amanuma H; Onuma M
Leukemia; 1997 Apr; 11 Suppl 3():223-6. PubMed ID: 9209348
[TBL] [Abstract][Full Text] [Related]
31. Immunoaffinity purification of two major proteins of bovine leukemia virus (gp51 and p24) and their use for discrimination between vaccinated and infected animals.
Merza M; Sundquist B; Söber J; Morein B
J Virol Methods; 1991 Aug; 33(3):345-53. PubMed ID: 1723735
[TBL] [Abstract][Full Text] [Related]
32. A synthetic peptide to the E glycoprotein of Murray Valley encephalitis virus defines multiple virus-reactive T- and B-cell epitopes.
Mathews JH; Roehrig JT; Brubaker JR; Hunt AR; Allan JE
J Virol; 1992 Nov; 66(11):6555-62. PubMed ID: 1383567
[TBL] [Abstract][Full Text] [Related]
33. Analysis of the neutralizing antibody response to the measles virus using synthetic peptides of the haemagglutinin protein.
Muller CP; Schroeder T; Tu R; Brons NH; Jung G; Schneider F; Wiesmüller KH
Scand J Immunol; 1993 Nov; 38(5):463-71. PubMed ID: 7694357
[TBL] [Abstract][Full Text] [Related]
34. Reduced humoral immunity and atypical cell-mediated immunity in response to vaccination in cows naturally infected with bovine leukemia virus.
Frie MC; Sporer KR; Wallace JC; Maes RK; Sordillo LM; Bartlett PC; Coussens PM
Vet Immunol Immunopathol; 2016 Dec; 182():125-135. PubMed ID: 27863543
[TBL] [Abstract][Full Text] [Related]
35. Prediction of B cell and T-helper cell epitopes candidates of bovine leukaemia virus (BLV) by in silico approach.
Hooshmand N; Fayazi J; Tabatabaei S; Ghaleh Golab Behbahan N
Vet Med Sci; 2020 Nov; 6(4):730-739. PubMed ID: 32592322
[TBL] [Abstract][Full Text] [Related]
36. Expression of the bovine leukemia virus envelope glycoprotein (gp51) by recombinant baculovirus and its use in an enzyme-linked immunosorbent assay.
De Giuseppe A; Feliziani F; Rutili D; De Mia GM
Clin Diagn Lab Immunol; 2004 Jan; 11(1):147-51. PubMed ID: 14715562
[TBL] [Abstract][Full Text] [Related]
37. Identification of Mengo virus T helper cell epitopes.
Muir S; Kobasa D; Bittle J; Scraba D
J Gen Virol; 1994 Nov; 75 ( Pt 11)():2925-36. PubMed ID: 7525861
[TBL] [Abstract][Full Text] [Related]
38. gammadelta(+) T-Lp6phocyte cytotoxicity against envelope-expressing target cells is unique to the alymphocytic state of bovine leukemia virus infection in the natural host.
Lundberg P; Splitter GA
J Virol; 2000 Sep; 74(18):8299-306. PubMed ID: 10954528
[TBL] [Abstract][Full Text] [Related]
39. T helper cell-independent neutralizing B cell response against vesicular stomatitis virus: role of antigen patterns in B cell induction?
Bachmann MF; Hengartner H; Zinkernagel RM
Eur J Immunol; 1995 Dec; 25(12):3445-51. PubMed ID: 8566036
[TBL] [Abstract][Full Text] [Related]
40. Increase of cells expressing PD-L1 in bovine leukemia virus infection and enhancement of anti-viral immune responses in vitro via PD-L1 blockade.
Ikebuchi R; Konnai S; Shirai T; Sunden Y; Murata S; Onuma M; Ohashi K
Vet Res; 2011 Sep; 42(1):103. PubMed ID: 21943148
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
